-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Reports 100% Response Rate in Six Evaluable Patients in Recurrent Glioblastoma Trial

PUBT·11/16/2026 11:21:14
Listen to the news
Alpha Tau Reports 100% Response Rate in Six Evaluable Patients in Recurrent Glioblastoma Trial
  • Alpha Tau Medical announced positive interim results from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma.
  • All eight treated patients remained alive as of November 11, 2026; all six evaluable patients showed tumor responses, mostly complete responses.
  • Treatment was delivered as planned in every patient, with no unanticipated serious adverse events.
  • No definitive local recurrence was observed, though some imaging findings remain unresolved between radiation-related tissue damage and tumor progression.
  • The results were presented at the Society for Neuro-Oncology annual meeting, held November 12-15, 2026, in Philadelphia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-120072), on November 16, 2026, and is solely responsible for the information contained therein.